U.S. markets closed
  • S&P 500

    +51.87 (+1.60%)
  • Dow 30

    +358.56 (+1.34%)
  • Nasdaq

    +241.26 (+2.26%)
  • Russell 2000

    +23.09 (+1.59%)
  • Crude Oil

    -0.27 (-0.67%)
  • Gold

    -12.60 (-0.67%)
  • Silver

    -0.21 (-0.91%)

    -0.0037 (-0.31%)
  • 10-Yr Bond

    -0.0070 (-1.05%)

    -0.0007 (-0.06%)

    +0.1570 (+0.15%)

    +3.24 (+0.03%)
  • CMC Crypto 200

    +12.36 (+5.67%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.82 (+0.51%)

Today's Research Reports on Trending Tickers: Titan Pharmaceuticals and Amarin Corporation

NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to National Association of Realtors, housing sales were down 3.4 percent in August, the lowest level since November 2015. The Dow Jones Industrial Average gained 0.26 percent to close at 25,444.34, while the S&P 500 Index dropped 0.04 percent to close at 2,767.78. The Nasdaq Composite Index declined 0.48 percent to close at 7,449.03.

“The weakness among home builders is likely dragging us a down a bit today,” said vice president of investment strategy at E-Trade, Mike Loewengart. “Let’s not forget October is a spooky month for the markets, where big gains and losses can disappear quick. This truly is a dogfight between the bulls and the bears, and really between strong fundamentals and nagging issues right on the horizon. What we’re seeing though is some consolidation as the market tries to find its course,” Loewengart said.

RDI Initiates Coverage on:

Titan Pharmaceuticals, Inc.

Amarin Corporation plc

Titan Pharmaceuticals' stock jumped 18.25% Friday, to close the day at $0.3784. The stock recorded a trading volume of 55,653,572 shares, which was above its three months average volume of 3,564,830 shares. In the last year, Titan Pharmaceuticals' shares have traded in a range of 0.17 - 2.85. The share price has gained 120% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.39 is below its 200-day moving average of $0.78. Shares of Titan Pharmaceuticals have gained roughly 74.62 percent in the past month and are down 71.44 percent year-to-date.

Access RDI's Titan Pharmaceuticals, Inc. Research Report at:

On Friday, shares of Amarin Corporation recorded a trading volume of 8,591,508 shares, which was below the three months average volume of 13,567,340 shares. The stock ended the day 1.99% lower at $19.71. The share price has fallen 7.03% from its 52 week high with a 52 week trading range of 2.35 - 21.20. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $11.60 is above its 200-day moving average of $5.09. Shares of Amarin Corporation have gained roughly 559.2 percent in the past month and are up 391.52 percent year-to-date.

Access RDI's Amarin Corporation plc Research Report at:

Our Actionable Research on Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Amarin Corporation plc (NASDAQ: AMRN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:




CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com